Poxel has a rich pipeline of first-in-class products with innovative, disease-modifying mechanisms of action. It owns intellectual property rights or has secured worldwide exclusive licenses for its entire portfolio.

The company's business model is based on maximal value creation for each of these compounds up to clinical proof-of-concept. Poxel does not intend to carry out Phase III development internally and will be looking for the ideal pharmaceutical partner(s) to take on late-stage clinical development and commercialization of its products. Poxel is retaining various options for future financing in accordance with its vision.